"By sheer numbers, it' s a huge pool of people that immunizations could really
reach and make an enormous impact." So one surveyed physician describes the
potential impact of vaccines for infectious disease. Indeed, the size of the
population is one reason why companies are taking a fresh look at the vaccine
sector. An increasing global reach, clinical accomplishments, strides in
establishing vaccine safety and manufacturer security, and ongoing unmet needs
are also fueling vaccine development.
Questions Answered in This Report:
- The vaccine marketplace is highly concentrated. What is the size of
this market, and what is its growth trend? Which companies are the leaders
based on 2010 sales? Will those rankings change? What opportunities are
available to these and other contenders in the vaccines space?
- Pfizer bought its way into the upper echelons of the vaccine marketplace
by acquiring Wyeth in 2009. Why would a company like Pfizer be attracted to
a potential acquiree' s vaccine assets? What other notable recent deals have
occurred in the vaccines arena?
- Shortly after HIV was identified as the cause of AIDS in the early 1980s,
Health and Human Services Secretary Margaret Heckler famously declared that a
vaccine would be available within two years. What is the status of HIV
vaccine development? What challenges must researchers confront? What are the
considerations related to prophylactic versus therapeutic vaccines for HIV?
- In December 2010, the FDA approved Merck' s Gardasil for the prevention of
anal cancers. What is next for Gardasil and GlaxoSmithKline' s Cervarix?
What impact will their availability have on approaches to immunization for
- Studies have shown that vaccines are not the cause of autism. How is
this finding influencing perceptions of vaccine safety, according to surveyed
clinicians? What other steps are being taken to ensure vaccine safety - and
vaccine manufacturer security?
- Emerging markets are drawing the attention of pharmaceutical companies,
including vaccine manufacturers. What are the pros and cons of selling
vaccines in emerging markets? Which companies have established a notable
presence in emerging markets?
Primary research: Results from a Web-based survey of 106 U.S.
physicians who administer infectious disease vaccines: infectious disease
specialists, pediatricians, and primary care physicians (PCPs).
Market size: Worldwide and U.S. market size over 2005-2017; key
competitors and their market share; market drivers and constraints.
Unmet needs: By segment, age-group, pathogen, and need in the clinical
Salient events and trends: HIV vaccine development, prime-boost
approach, RV-144, broadly active neutralizing antibodies (bnAbs), therapeutic
versus prophylactic HIV vaccines, HPV vaccinations, adolescent immunization
schedules, vaccine safety, vaccine/autism link, vaccine needs and challenges
in emerging markets.
Deals: Select mergers, acquisitions, and partnerships and how they
demonstrate opportunity and strategy.
Displays: 27 data-rich tables and figures.